Geographic atrophy (GA) represents the advanced stage of dry age-related macular degeneration (AMD), causing progressive and irreversible loss of central vision. While historically lacking effective treatments, recent breakthroughs offer hope for slowing this vision-threatening condition. Understanding GA empowers patients and families to make informed decisions and access emerging therapies.
What is Geographic Atrophy?
Geographic atrophy is an advanced form of dry age-related macular degeneration characterized by progressive death of retinal cells in the macula—the central part of the retina responsible for sharp, detailed vision. As these cells die, they leave behind distinct patches of atrophy (tissue loss) that gradually expand over time, creating a "geographic" pattern visible during eye examinations.
The name "geographic atrophy" comes from the appearance of these atrophic areas, which resemble continents or islands on a map when viewed through specialized imaging. As the atrophy expands and potentially involves the fovea (the very center of the macula), central vision progressively deteriorates.
GA is a Form of Dry AMD
Unlike wet AMD (which involves abnormal blood vessel growth), geographic atrophy is the late stage of dry AMD, characterized by gradual cell death rather than leaking blood vessels. However, some patients can develop both forms simultaneously.
Prevalence: A Growing Concern
As the population ages, geographic atrophy affects an increasing number of people:
Current Impact
Approximately 5 million people worldwide have geographic atrophy, with about 1 million in the United States. This number is expected to increase significantly as the population ages.
Risk factors include:
- Age: Most common in people over 60, with increasing prevalence after 75
- History of dry AMD: GA develops from earlier stages of dry AMD
- Family history: Genetic factors play a significant role
- Smoking: Doubles or triples the risk of progression to GA
- Caucasian ethnicity: Higher prevalence than other ethnic groups
- Cardiovascular disease: Shared risk factors with AMD
- Light-colored eyes: May have slightly increased risk
- Obesity: Associated with faster progression
How Geographic Atrophy Develops
GA doesn't appear suddenly—it develops through a progression of dry AMD stages:
Early Dry AMD
Small or few medium-sized drusen (yellow deposits under the retina). Usually no symptoms or vision loss. Regular monitoring is essential.
Intermediate Dry AMD
Many medium-sized drusen or one or more large drusen. May have mild vision changes, particularly difficulty with reading or low-light vision. Increased risk of progression to advanced stages.
Advanced Dry AMD (Geographic Atrophy)
Breakdown of light-sensitive cells and supporting tissue in the macula. Well-defined areas of retinal atrophy. Progressive, irreversible vision loss as atrophy expands. Can eventually involve the fovea, causing severe central vision loss.
The transition from intermediate AMD to GA is not inevitable, but the risk increases significantly with certain genetic markers, lifestyle factors, and disease characteristics.
Symptoms: Impact on Daily Life
Geographic atrophy typically progresses slowly over years, with symptoms gradually worsening as the atrophic area expands:
Early GA symptoms:
- Blurred or distorted central vision: Straight lines may appear wavy
- Difficulty reading: Letters seem to disappear or words blur
- Dark or blank spots in central vision: Initially small but expanding
- Reduced contrast sensitivity: Difficulty distinguishing similar shades
- Trouble with face recognition: Central features become unclear
- Need for brighter light: Especially for reading and close work
As GA progresses:
- Expanding central blind spot: Makes reading increasingly difficult
- Severe difficulty with detail work: Sewing, writing, or other precision tasks become challenging
- Inability to recognize faces: Even of familiar people
- Difficulty with color perception: Colors appear washed out
- Problems with activities of daily living: Cooking, managing medications, personal care
- Driving difficulties: Eventually may need to stop driving
Peripheral Vision Typically Preserved
An important characteristic of GA is that peripheral (side) vision usually remains intact, even in advanced stages. While central vision is severely affected, you can still navigate spaces and avoid obstacles using your peripheral vision.
Diagnosis: Detecting and Monitoring GA
Comprehensive eye examinations and specialized imaging are essential for detecting and tracking GA:
Clinical Examination
- Dilated fundus exam: Direct visualization of retinal changes
- Visual acuity testing: Measuring how well you can see at various distances
- Amsler grid: Simple home test to detect distortion or missing areas in central vision
Advanced Imaging
- Optical coherence tomography (OCT): Cross-sectional images showing retinal layers and areas of atrophy in detail
- Fundus autofluorescence (FAF): Highlights areas of geographic atrophy and can predict progression risk
- Color fundus photography: Documents the appearance and extent of atrophy over time
- OCT angiography: Evaluates blood flow and can help distinguish from wet AMD
These imaging techniques not only diagnose GA but also measure the size and growth rate of atrophic areas, which is crucial for monitoring progression and evaluating treatment responses.
Current Treatment Landscape
For decades, no treatments existed to slow geographic atrophy. However, recent breakthroughs have begun to change this landscape:
Recently Approved Treatments
In 2023, the FDA approved the first treatments specifically for geographic atrophy:
Pegcetacoplan (Syfovre) and Avacincaptad Pegol (Izervay)
Complement inhibitors that target inflammatory pathways involved in GA progression. Administered as intravitreal injections (into the eye). Clinical trials showed modest slowing of atrophy growth—approximately 20-36% reduction in growth rate over 12-24 months. Require regular injections (monthly or every other month). Represent the first FDA-approved treatments specifically for GA.
Important considerations:
- These treatments slow but do not stop progression
- Cannot reverse existing damage or restore lost vision
- Effectiveness varies among individuals
- Small risk of conversion to wet AMD (appears slightly increased with treatment)
- Long-term safety and efficacy still being evaluated
- Significant cost considerations
Nutritional Supplementation
Based on the AREDS2 study, high-dose vitamins and minerals may slow progression in people with intermediate AMD and reduce risk of advancing to GA:
AREDS2 formula:
- Vitamin C (500 mg)
- Vitamin E (400 IU)
- Lutein (10 mg)
- Zeaxanthin (2 mg)
- Zinc (80 mg)
- Copper (2 mg)
However, once GA has developed, the benefit of these supplements is less clear. They may help slow progression in the fellow eye if it doesn't yet have GA.
Lifestyle Modifications
- Stop smoking: Most important modifiable risk factor
- Healthy diet: Mediterranean diet rich in leafy greens, fish, and colorful vegetables
- UV protection: Wear sunglasses with UV protection
- Cardiovascular health: Control blood pressure, cholesterol, and maintain healthy weight
- Regular exercise: Benefits overall and eye health
Emerging and Investigational Treatments
The pipeline for GA treatments is promising, with numerous therapies in clinical trials:
- Alternative complement inhibitors: Targeting different parts of the inflammatory cascade
- Gene therapy: Attempting to deliver protective genes to retinal cells
- Stem cell therapy: Investigating replacement of damaged retinal cells
- Neuroprotection strategies: Protecting remaining cells from death
- Anti-inflammatory agents: Targeting chronic inflammation
- Combination therapies: Using multiple approaches simultaneously
Participation in clinical trials may provide access to cutting-edge treatments while contributing to scientific knowledge.
Living with Geographic Atrophy
While GA significantly impacts vision, many strategies and resources can help maintain independence and quality of life:
Low Vision Rehabilitation
- Low vision specialists: Eye doctors specializing in maximizing remaining vision
- Magnifying devices: Handheld, stand, and electronic magnifiers
- Telescopic glasses: Help with distance viewing
- Large-print materials: Books, newspapers, playing cards, and labels
- High-contrast items: Easier to see than similar shades
- Improved lighting: Brighter, focused task lighting
Assistive Technology
- Screen readers and text-to-speech software: Computer and smartphone accessibility
- Voice-activated devices: Smart speakers and assistants
- Audiobooks and podcasts: Entertainment and information
- Large-button phones and appliances
- Video magnifiers (CCTV systems): Electronic devices that significantly enlarge text and images
- Apps designed for low vision: Magnification, contrast enhancement, color identification
Occupational Therapy
- Training in using assistive devices effectively
- Home safety modifications
- Techniques for daily activities like cooking and personal care
- Eccentric viewing training (using peripheral vision to compensate for central scotoma)
Emotional and Social Support
- Counseling: Coping with vision loss and maintaining mental health
- Support groups: Connect with others facing similar challenges
- Organizations: Resources from groups like the American Macular Degeneration Foundation and BrightFocus Foundation
- Vocational rehabilitation: For those still working
Monitoring and Follow-Up
Regular monitoring is essential for people with GA:
- Frequent eye exams: Every 3-6 months or as recommended
- Imaging studies: Track atrophy growth and detect complications
- Home monitoring: Daily Amsler grid testing to detect sudden changes
- Fellow eye monitoring: If only one eye has GA, the other eye needs close watching
- Watch for wet AMD: GA patients remain at risk for developing wet AMD, which requires urgent treatment
Report Sudden Changes Immediately
If you notice sudden worsening of vision, new distortion, or rapid change in your symptoms, contact your eye doctor immediately. This could indicate development of wet AMD, which requires prompt treatment.
Research and Hope for the Future
The field of GA treatment is rapidly evolving:
- Multiple new drugs in late-stage clinical trials
- Better understanding of disease mechanisms guiding drug development
- Improved imaging allowing earlier detection and better monitoring
- Artificial intelligence helping predict progression and optimize treatment
- Combination therapies showing promise
- Regenerative medicine approaches advancing
While current treatments provide modest benefit, the rapid pace of research offers genuine hope for more effective therapies in the coming years.
Conclusion
Geographic atrophy presents significant challenges, causing progressive central vision loss that impacts daily life. However, the landscape is changing. For the first time, treatments exist that can slow progression, and many more are in development. Combined with low vision rehabilitation, assistive technology, and strong support systems, people with GA can maintain independence and quality of life. If you have intermediate AMD or are at high risk, work closely with your eye care team, consider appropriate preventive measures, and stay informed about emerging treatments. Early detection and proactive management offer the best chance of preserving your vision as long as possible.
Diagnosed with Geographic Atrophy?
Connect with a retina specialist experienced in the latest GA treatments and low vision rehabilitation to optimize your vision and quality of life.
Find a GA Specialist